Phreesia, Inc. (NYSE:PHR) Shares Sold by Riverbridge Partners LLC

Riverbridge Partners LLC lowered its position in Phreesia, Inc. (NYSE:PHR) by 9.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 683,888 shares of the company’s stock after selling 69,341 shares during the quarter. Riverbridge Partners LLC owned about 1.18% of Phreesia worth $17,207,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in PHR. Deerfield Management Company L.P. Series C bought a new stake in Phreesia during the 2nd quarter valued at $4,078,000. Champlain Investment Partners LLC raised its stake in shares of Phreesia by 4.1% during the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after purchasing an additional 97,847 shares in the last quarter. Sei Investments Co. lifted its holdings in Phreesia by 135.3% in the second quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock worth $3,505,000 after purchasing an additional 95,058 shares during the period. Squarepoint Ops LLC raised its position in shares of Phreesia by 56.3% during the 2nd quarter. Squarepoint Ops LLC now owns 250,396 shares of the company’s stock worth $5,308,000 after buying an additional 90,215 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after acquiring an additional 88,517 shares during the period. Institutional investors own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. JMP Securities restated a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research report on Tuesday, December 10th. KeyCorp increased their target price on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, January 8th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and lifted their price target for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Citigroup increased their price objective on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Finally, Robert W. Baird reduced their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $31.00.

Phreesia Stock Down 0.2 %

PHR opened at $27.29 on Thursday. The company has a market capitalization of $1.59 billion, a PE ratio of -18.56 and a beta of 0.94. The business has a 50-day moving average of $23.87 and a 200-day moving average of $22.97. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $29.16. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. During the same period in the previous year, the company earned ($0.58) earnings per share. The company’s revenue was up 16.6% compared to the same quarter last year. Equities research analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Insider Activity

In related news, CFO Balaji Gandhi sold 3,195 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $26.61, for a total transaction of $85,018.95. Following the completion of the sale, the chief financial officer now directly owns 148,509 shares of the company’s stock, valued at approximately $3,951,824.49. This represents a 2.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Amy Beth Vanduyn sold 4,720 shares of Phreesia stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $27.31, for a total transaction of $128,903.20. Following the completion of the transaction, the senior vice president now owns 110,309 shares in the company, valued at $3,012,538.79. This trade represents a 4.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 131,756 shares of company stock valued at $3,244,909. Insiders own 5.80% of the company’s stock.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.